Details for 2016202983

Up to date per 04.04.2026

Actions

Title / Product Name

N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3-METHYLAZETIDIN-1-SULFONAMID ALS CHEMOKINREZEPTORMODULATOR

Status

Deleted

Protection Type

European Patent

(AT-) Application Number

2016202983

EP Publication Number

3255043

E-Number

1356289

Language

PCT Number

Publication Date

13.12.2017 A

20.01.2021 B1

Registration Date

20.01.2021

AT Publication Date

15.02.2021

Application Date

10.07.2012

Registration Number

Priorities

12.07.2011

201161506737 P

IPC

C07D 403/12 20060101AFI20180314BHEP

Maximum Duration of Protection

10.07.2032

Owner

AstraZeneca AB 151 85 SödertäljeSE

Representative

Häupl & Ellmeyer KG, PatentanwaltskanzleiMariahilfer Straße 50 (Eingang Kirchengasse 1)1070 WienAT

Inventor

CONNOLLY, Stephenc/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley Alderley Park Macclesfield, Cheshire SK10 4GTGB

EBDEN, Mark, RichardC/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley Alderley Park Macclesfield, Cheshire SK10 4TGGB

LANGER, ThomasAstraZeneca Charter Way Macclesfield, Cheshire SK10 2NAGB

STEVEN, Alan, RobertAstraZeneca Charter Way Macclesfield, Cheshire SK10 2NAGB

STEWART, Craig, RobertAstraZeneca, Charter Way Macclesfield, Cheshire SK10 2NAGB

TOMLIN, Paula, MargaretAstraZeneca Charter Way Macclesfield, Cheshire SK10 2NAGB

WALTERS, Iain, Alastair, StewartC/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley Alderley Park Macclesfield, Cheshire SK10 4TGGB

WILLIAMS, Andrew, JohnAstraZeneca, Alderley Park Macclesfield, Cheshire SK10 4TGGB